학술논문
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Document Type
Article
Author
Source
In: The Lancet Haematology . (The Lancet Haematology, August 2021, 8(8):e562-e571)
Subject
Language
English
ISSN
23523026